UCB emerged as a major biopharmaceutical player in the 1990s with the development of blockbuster drugs Zyrtec and Keppra. Throughout the 1990s and early 2000s, UCB transformed from a hybrid ...

Evenity is approved in a niche indication with a limit of 12 months use due to side effects. While we expect solid growth from Evenity, we don't think its earnings will contribute to a moat for UCB.

Rob Demovsky of ESPN.com reports that “strong indications” in Green Bay are that Alexander has played his final down for the team. Alexander’s unavailability is the biggest reason why the team is ...

"I would say that, if you are watching and there's not a lot of movement, that's a good indication that there is not a lot of arrests going on," Fleischaker commented. CBS 8 also spent about 8 ...

Rob Demovsky of ESPN.com reports that "strong indications" in Green Bay are that Alexander has played his final down for the team. Alexander's unavailability is the biggest reason why the team is ...

CANANDAIGUA, N.Y. (WROC) — The Ontario County District Attorney sent out a press release Sunday saying while the investigation is ongoing, they have no indication that the death of Sam Nordquist was a ...

Repatha, which treats cholesterol and heart disease, and EVENITY, which targets osteoporosis ... Launches in new indications for UPLIZNA, which treats neuromyelitis optica spectrum disorder ...

PRODUCTS such as Bonuan bangus, pilinuts from Bicol and the Tboli people's T'nalak cloth are being considered for geographical indication (GI) certification by the Intellectual Property Office of the ...

Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity ... that is an indication that they expect the ...

Amgen Inc. (NASDAQ:AMGN) Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations were $5.04. Operator: My name is Julienne ...

Amgen's diversified portfolio includes 14 blockbuster medicines, with standout growth in Repatha and Evenity, and promising pipeline developments, particularly for MariTide. Despite patent ...